FLR logo

Fluor Corporation (FLR)

$47.67

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on FLR

Market cap

$6.38B

EPS

-11.81

P/E ratio

--

Price to sales

0.44

Dividend yield

--

Beta

1.280064

Price on FLR

Previous close

$47.63

Today's open

$47.06

Day's range

$45.40 - $47.77

52 week range

$39.33 - $58.35

Profile about FLR

CEO

David E. Constable

Employees

26866

Headquarters

Irving, TX

Exchange

New York Stock Exchange

Shares outstanding

133741067

Issue type

Common Stock

FLR industries and sectors

Industrials

Construction

News on FLR

Is Fluor (FLR) Stock Outpacing Its Construction Peers This Year?

Here is how Fluor (FLR) and Legence (LGN) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Oct 8, 2026

news preview

Fluor Corporation to Hold Third Quarter Earnings Conference Call

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) will hold a conference call to review results for its third quarter ended September 30, 2026. The public is invited to listen to the conference call on Friday, November 6, 2026, at 8:30 a.m. Eastern with Chief Executive Officer Jim Breuer and Chief Financial Officer John Regan. Financial results will be released prior to the market open that day. The live webcast and a reply will be available with accompanying slides online at invest.

news source

Business Wire • Oct 1, 2026

news preview

Fluor-JGC JV Selected for LNG Canada Phase 2 Expansion Project

FLR's JGC joint venture will execute LNG Canada Phase 2, with Fluor set to recognize a $7.5 billion share as production capacity is poised to double.

news source

Zacks Investment Research • Sep 30, 2026

news preview

Shell Greenlights LNG Canada Phase 2, Doubling Export Capacity

SHEL greenlights LNG Canada Phase 2, doubling capacity to 28 mtpa and securing nearly 6 mtpa of additional LNG from the project.

news source

Zacks Investment Research • Sep 30, 2026

news preview

New Industry Survey Reinforces Nuclear's Growth Outlook

The owners and operators of commercial reactors in the U.S. are planning for a larger and longer-lasting fleet. A recent survey of utility companies from the Nuclear Energy Institute (NEI) highlights rising interest in new reactors and expectations for operating lives beyond 80 years.

news source

ETF Trends • Sep 28, 2026

news preview

Are Construction Stocks Lagging Fluor (FLR) This Year?

Here is how Fluor (FLR) and Owens Corning (OC) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Sep 22, 2026

news preview

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

news source

Benzinga • Sep 20, 2026

news preview

(PODCAST) Voyageur Pharmaceuticals (TSXV:VM) Achieves First Milestone in Bayer Collaboration, Secures USD $1 Million Payment

CALGARY, Alberta — September 10 , 2026 — Leads & Copy — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF), a Canadian company focused on developing pharmaceutical-grade barium and iodine contrast media for medical imaging, has achieved its first milestone under a non-dilutive Collaboration and Funding Agreement with Bayer AG. The company announced that it successfully submitted a complete feasibility work plan and timetable, which has been approved by Bayer. The milestone achievement triggers the first major non-dilutive payment of USD $1,000,000 from Bayer. This payment, combined with the initial USD $350,000 received on March 31, 2026, brings the total funding received by Voyageur from Bayer to USD $1,350,000 of the committed USD $2,350,000.

news preview

Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment

CALGARY, Alberta – TheNewswire - September 9, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has achieved the first milestone under its non-dilutive Collaboration and Funding Agreement with Bayer AG (“ Bayer ”) dated February 10, 2026 (the  “ Agreement ”) by submitting a complete feasibility work plan and timetable which has been approved by Bayer. (Collaboration funding news https://finance.yahoo.com/news/voyageur-pharmaceuticals-announces-collaboration-bayer-144926270.html )

news preview

Construction Firms Powering the Nuclear Renaissance

Investors usually focus on reactor developers and uranium miners when deciding on allocations for investing in the nuclear renaissance. A narrow view on the nuclear sector could result in missed opportunities for investment returns in nuclear-adjacent companies.

news source

ETF Trends • Sep 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Fluor Corporation

Open an M1 investment account to buy and sell Fluor Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in FLR on M1